Correlation Between Immunovant and Ascendis Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Immunovant and Ascendis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunovant and Ascendis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Immunovant and Ascendis Pharma AS, you can compare the effects of market volatilities on Immunovant and Ascendis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunovant with a short position of Ascendis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunovant and Ascendis Pharma.

Diversification Opportunities for Immunovant and Ascendis Pharma

-0.03
  Correlation Coefficient

Good diversification

The 3 months correlation between Immunovant and Ascendis is -0.03. Overlapping area represents the amount of risk that can be diversified away by holding Immunovant and Ascendis Pharma AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ascendis Pharma AS and Immunovant is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunovant are associated (or correlated) with Ascendis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ascendis Pharma AS has no effect on the direction of Immunovant i.e., Immunovant and Ascendis Pharma go up and down completely randomly.

Pair Corralation between Immunovant and Ascendis Pharma

Given the investment horizon of 90 days Immunovant is expected to under-perform the Ascendis Pharma. In addition to that, Immunovant is 1.29 times more volatile than Ascendis Pharma AS. It trades about -0.16 of its total potential returns per unit of risk. Ascendis Pharma AS is currently generating about 0.03 per unit of volatility. If you would invest  12,944  in Ascendis Pharma AS on August 28, 2024 and sell it today you would earn a total of  141.00  from holding Ascendis Pharma AS or generate 1.09% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Immunovant  vs.  Ascendis Pharma AS

 Performance 
       Timeline  
Immunovant 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Ascendis Pharma AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ascendis Pharma AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Ascendis Pharma is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Immunovant and Ascendis Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Immunovant and Ascendis Pharma

The main advantage of trading using opposite Immunovant and Ascendis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunovant position performs unexpectedly, Ascendis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ascendis Pharma will offset losses from the drop in Ascendis Pharma's long position.
The idea behind Immunovant and Ascendis Pharma AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Bonds Directory
Find actively traded corporate debentures issued by US companies
Money Managers
Screen money managers from public funds and ETFs managed around the world
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency